---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-027037"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T12:56:20.337407+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Capricor FY2025 net loss $105M; Deramiocel PDUFA date Aug 22, 2026

## Summary
- Net loss of $30.2M in Q4 2025 ($0.62/sh) and $105.0M for FY2025 ($2.26/sh).
- Revenue was $0 in Q4 and FY2025, vs $11.1M and $22.3M in prior-year periods, as Nippon Shinyaku milestones fully recognized.
- Cash, equivalents and marketable securities $318.1M at Dec 31, 2025, up from $151.5M; expected to fund operations through 2027.
- BLA for Deramiocel in Duchenne muscular dystrophy under FDA review; PDUFA target date August 22, 2026.
- Phase 3 HOPE-3 trial met primary endpoint (PUL v2.0, p=0.03) and key cardiac endpoint (LVEF, p=0.04).

## SEC filing metadata
- accession: 0001104659-26-027037
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000110465926027037/0001104659-26-027037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000110465926027037/capr-20260312x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-027037
- JSON: https://secwatch.observer/filing/0001104659-26-027037.json
- Plain text: https://secwatch.observer/filing/0001104659-26-027037.txt

## Key facts
- Earnings Releases
  CAPRICOR THERAPEUTICS, INC. reported the fourth quarter ended December 31, 2025 results: revenue $0.
  - Period: the fourth quarter ended December 31, 2025
  - Revenue: $0
  - Result: reported results
  source text: Revenues for the fourth quarter of 2025 were $0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133869/000110465926027037/0001104659-26-027037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.